Chau-Ting Yeh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1137605/publications.pdf

Version: 2024-02-01

208 papers 5,304 citations

35 h-index 61 g-index

209 all docs

209 docs citations

times ranked

209

5948 citing authors

#	Article	IF	Citations
1	Globo H Is a Promising Theranostic Marker for Intrahepatic Cholangiocarcinoma. Hepatology Communications, 2022, 6, 194-208.	4.3	9
2	CMAHP promotes metastasis by reducing ubiquitination of Snail and inducing angiogenesis via GM-CSF overexpression in gastric cancer. Oncogene, 2022, 41, 159-172.	5.9	7
3	Functional Role of Mitochondrial DNA in Cancer Progression. International Journal of Molecular Sciences, 2022, 23, 1659.	4.1	28
4	GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Hepatology International, 2022, 16, 148.	4.2	6
5	Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan. Journal of Hepatology, 2022, 77, 63-70.	3.7	2
6	COX5B-Mediated Bioenergetic Alterations Modulate Cell Growth and Anticancer Drug Susceptibility by Orchestrating Claudin-2 Expression in Colorectal Cancers. Biomedicines, 2022, 10, 60.	3.2	5
7	Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan. Clinical Therapeutics, 2022, 44, 403-417.e6.	2.5	2
8	Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy. Anticancer Research, 2022, 42, 2479-2486.	1.1	2
9	Child–Pugh Score and ABCG2-rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib. Journal of Clinical Medicine, 2022, 11, 2550.	2.4	3
10	Anticoagulant drugs with or without proton pump inhibitor and colorectal cancer risk: a population-based, case–control study. BMC Gastroenterology, 2022, 22, 225.	2.0	0
11	Reduction of ACE2 serum concentrations by telbivudine in chronic hepatitis B patients. Current Molecular Medicine, 2022, 22, .	1.3	2
12	Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. Biomedicines, 2022, 10, 1232.	3.2	3
13	Epidemiology changes in peptic ulcer diseases 18 years apart explored from the genetic aspects of Helicobacter pylori. Translational Research, 2021, 232, 115-120.	5.0	7
14	Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients. BMC Gastroenterology, 2021, 21, 177.	2.0	13
15	Direct-acting Antiviral Therapy Improves the Outcome of Chronic Hepatitis C/intermediate-stage B Hepatocellular Carcinoma Patients. Anticancer Research, 2021, 41, 2007-2016.	1.1	4
16	LINC01348 suppresses hepatocellular carcinoma metastasis through inhibition of SF3B3-mediated EZH2 pre-mRNA splicing. Oncogene, 2021, 40, 4675-4685.	5.9	18
17	Clinical Limitations of Tissue Annexin A2 Level as a Predictor of Postoperative Overall Survival in Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2021, 10, 4158.	2.4	3
18	The Aldehyde Dehydrogenase ALDH2*2 Allele, Associated with Alcohol Drinking Behavior, Dates Back to Prehistoric Times. Biomolecules, 2021, 11, 1376.	4.0	3

#	Article	IF	Citations
19	Liver-lobule-mimicking patterning via dielectrophoresis and hydrogel photopolymerization. Sensors and Actuators B: Chemical, 2021, 343, 130159.	7.8	12
20	Impact of an MT-RNR1 Gene Polymorphism on Hepatocellular Carcinoma Progression and Clinical Characteristics. International Journal of Molecular Sciences, 2021, 22, 1119.	4.1	10
21	Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression. Cancers, 2021, 13, 538.	3.7	7
22	The lipid peroxidation derived DNA adduct \hat{I}^3 -OHPdG levels in paraneoplastic liver tissues predict postoperative outcomes of hepatoma. Journal of Cancer, 2021, 12, 4064-4074.	2.5	4
23	Antioxidant properties of red raspberry extract alleviate hepatic fibrosis via inducing apoptosis and transdifferentiation of activated hepatic stellate cells. Biomedicine and Pharmacotherapy, 2021, 144, 112284.	5. 6	11
24	Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma. Biomedicines, 2021, 9, 1539.	3.2	3
25	Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer. Cancers, 2021, 13, 5361.	3.7	8
26	Overt Acute Hepatitis B Deteriorates in Females: Destructive Immunity With an Exaggerated Interleukin-17 Pathway. Frontiers in Immunology, 2021, 12, 631976.	4.8	0
27	SYNE1 Exonic Variant rs9479297 Contributes to Concurrent Hepatocellular and Transitional Cell Carcinoma Double Primary Cancer. Biomedicines, 2021, 9, 1819.	3.2	2
28	A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Pharmacogenomics Journal, 2020, 20, 57-68.	2.0	9
29	Decreasing seroprevalence of antiâ€hepatitis D virus antibodies in the antiviral era with inverse association with hepatitis B virus DNA, Taiwan, 2006 to 2019. Journal of Medical Virology, 2020, 92, 124-127.	5. O	5
30	Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients. Digestive Diseases and Sciences, 2020, 65, 2130-2139.	2.3	7
31	Impact of mixed cryoglobulinemia on patients with spontaneous hepatitis C virus clearance: A 13â€year prospective cohort study. European Journal of Clinical Investigation, 2020, 50, e13189.	3.4	5
32	Functional Compartmentalization of HSP60-Survivin Interaction between Mitochondria and Cytosol in Cancer Cells. Cells, 2020, 9, 23.	4.1	44
33	DOCK6 promotes chemo- and radioresistance of gastric cancer by modulating WNT/β-catenin signaling and cancer stem cell traits. Oncogene, 2020, 39, 5933-5949.	5.9	23
34	Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression. Hepatology International, 2020, 14, 973-984.	4.2	4
35	The Molecular Function and Clinical Role of Thyroid Stimulating Hormone Receptor in Cancer Cells. Cells, 2020, 9, 1730.	4.1	30
36	The effect of prophylactic hemoclip placement and risk factors of delayed post-polypectomy bleeding in polyps sized 6 to 20 millimeters: a propensity score matching analysis. BMC Gastroenterology, 2020, 20, 309.	2.0	4

3

#	Article	IF	Citations
37	Hepatitis B Virus preS/S Truncation Mutant rtM204l/sW196* Increases Carcinogenesis through Deregulated HIF1A, MGST2, and TGFbi. International Journal of Molecular Sciences, 2020, 21, 6366.	4.1	6
38	Thyroid Hormone in Hepatocellular Carcinoma: Cancer Risk, Growth Regulation, and Anticancer Drug Resistance. Frontiers in Medicine, 2020, 7, 174.	2.6	13
39	Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies. Cells, 2020, 9, 1331.	4.1	145
40	Radiosensitization of Hepatocellular Carcinoma through Targeting Radio-Associated MicroRNA. International Journal of Molecular Sciences, 2020, 21, 1859.	4.1	18
41	Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells. Frontiers in Oncology, 2020, 10, 216.	2.8	13
42	COX5B-Mediated Bioenergetic Alteration Regulates Tumor Growth and Migration by Modulating AMPK-UHMK1-ERK Cascade in Hepatoma. Cancers, 2020, 12, 1646.	3.7	20
43	Plasma phenylalanine and glutamine concentrations correlate with subsequent hepatocellular carcinoma occurrence in liver cirrhosis patients: an exploratory study. Scientific Reports, 2020, 10, 10926.	3.3	24
44	A Novel Long Non-Coding RNA-01488 Suppressed Metastasis and Tumorigenesis by Inducing miRNAs That Reduce Vimentin Expression and Ubiquitination of Cyclin E. Cells, 2020, 9, 1504.	4.1	10
45	GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers. International Journal of Molecular Sciences, 2020, 21, 1491.	4.1	27
46	TUG1 Is a Regulator of AFP and Serves as Prognostic Marker in Non-Hepatitis B Non-Hepatitis C Hepatocellular Carcinoma. Cells, 2020, 9, 262.	4.1	16
47	Dysregulated FAM215A Stimulates LAMP2 Expression to Confer Drug-Resistant and Malignant in Human Liver Cancer. Cells, 2020, 9, 961.	4.1	15
48	Hepatitis B Virus X Protein Induces RHAMM-Dependent Motility in Hepatocellular Carcinoma Cells via PI3K–Akt–Oct-1 Signaling. Molecular Cancer Research, 2020, 18, 375-389.	3.4	12
49	Aldolase triggers metabolic reprogramming in colorectal cancer in hypoxia and stiff desmoplastic microenvironments. Colloids and Surfaces B: Biointerfaces, 2020, 190, 110969.	5.0	7
50	Reply to Comments: "Molecular Functions of Thyroid Hormone Signaling in Regulation of Cancer Progression and Anti-Apoptosis―Int. J. Mol. Sci., 2019, 20, 4986. International Journal of Molecular Sciences, 2020, 21, 3554.	4.1	4
51	Thyroid hormones suppress FOXM1 expression to reduce liver cancer progression. Oncology Reports, 2020, 44, 1686-1698.	2.6	5
52	Structural Pattern Differences in Unbranched Rod-like RNA of Hepatitis Delta Virus affect RNA Editing. Viruses, 2019, 11, 934.	3.3	8
53	Molecular Functions of Thyroid Hormone Signaling in Regulation of Cancer Progression and Anti-Apoptosis. International Journal of Molecular Sciences, 2019, 20, 4986.	4.1	84
54	Roles of Thyroid Hormone-Associated microRNAs Affecting Oxidative Stress in Human Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 5220.	4.1	23

#	Article	IF	CITATIONS
55	Characterization of Fibrinogen as a Key Modulator in Patients with Wilson's Diseases with Functional Proteomic Tools. International Journal of Molecular Sciences, 2019, 20, 4528.	4.1	3
56	Characterization of the Roles of Vimentin in Regulating the Proliferation and Migration of HSCs during Hepatic Fibrogenesis. Cells, 2019, 8, 1184.	4.1	20
57	Factors associated with polyp detection during colonoscopy: A retrospective observational study. Kaohsiung Journal of Medical Sciences, 2019, 35, 572-577.	1.9	6
58	Dynamic bioenergetic alterations in colorectal adenomatous polyps and adenocarcinomas. EBioMedicine, 2019, 44, 334-345.	6.1	21
59	Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer. Theranostics, 2019, 9, 2361-2379.	10.0	25
60	Is there a sex difference in postoperative prognosis of hepatocellular carcinoma?. BMC Cancer, 2019, 19, 250.	2.6	15
61	Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in patients with chronic hepatitis B. Journal of Medical Virology, 2019, 91, 1360-1363.	5.0	1
62	Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases. Journal of Biomedical Science, 2019, 26, 24.	7.0	57
63	The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine. Cell Death and Disease, 2019, 10, 240.	6.3	36
64	Comparison of Compliance and Efficacy of Pegylated Interferon \hat{l}_{\pm} -2a and \hat{l}_{\pm} -2b in Adults with Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2019, 39, 205-213.	1.2	3
65	Diverse immune responses to HBV surface epitope variants after vaccine booster in adolescents immunized in infancy. Clinical Microbiology and Infection, 2019, 25, 1140-1146.	6.0	3
66	Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A populationâ€based cohort study. Journal of Viral Hepatitis, 2019, 26, 718-726.	2.0	31
67	The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine, 2019, 8, 2225.	2.4	4
68	The Defective Allele of Aldehyde Dehydrogenase 2 Gene is Associated with Favorable Postoperative Prognosis in Hepatocellular Carcinoma. Journal of Cancer, 2019, 10, 5735-5743.	2.5	8
69	Ages of hepatocellular carcinoma occurrence and life expectancy are associated with a UGT2B28 genomic variation. BMC Cancer, 2019, 19, 1190.	2.6	6
70	Emergence of Oncogenicâ€Enhancing Hepatitis B Virus X Gene Mutants in Patients Receiving Suboptimal Entecavir Treatment. Hepatology, 2019, 69, 2292-2296.	7.3	12
71	Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1530-1537.	2.8	3
72	Recovery of lipid metabolic alterations in hepatitis C patients after viral clearance: Incomplete restoration with accelerated i‰-oxidation. Journal of Clinical Lipidology, 2018, 12, 756-766.	1.5	12

#	Article	IF	Citations
73	Metabolic risk factors are associated with nonâ€hepatitis B nonâ€hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatology Communications, 2018, 2, 747-759.	4.3	35
74	Targeting HSP60 by subcutaneous injections of jetPEI/HSP60â€shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth. Molecular Carcinogenesis, 2018, 57, 1087-1101.	2.7	16
7 5	Combinations of single nucleotide polymorphisms <i>WWOX</i> â€rs13338697, <i>GALNT14</i> â€rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e54-e63.	1.1	10
76	Stimulation of Interferon-Stimulated Gene 20 by Thyroid Hormone Enhances Angiogenesis in Liver Cancer. Neoplasia, 2018, 20, 57-68.	5.3	21
77	Taurine upâ€regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. Hepatology, 2018, 67, 188-203.	7.3	123
78	Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication. International Journal of Molecular Sciences, 2018, 19, 3742.	4.1	48
79	Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and <i>GALNT14</i> Genotype. Journal of Cancer, 2018, 9, 3540-3547.	2.5	14
80	Melatonin Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy Through Long Non-Coding RNA RAD51-AS1-Mediated Suppression of DNA Repair. Cancers, 2018, 10, 320.	3.7	37
81	Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated RAF1 Reduction. International Journal of Molecular Sciences, 2018, 19, 2687.	4.1	32
82	Histidine-Dependent Protein Methylation Is Required for Compartmentalization of CTP Synthase. Cell Reports, 2018, 24, 2733-2745.e7.	6.4	36
83	A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e341-e351.	1.1	9
84	Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients. Open Forum Infectious Diseases, 2018, 5, ofx271.	0.9	3
85	Increase of Serum Kallikrein-8 Level After Long-term Telbivudine Treatment. In Vivo, 2018, 32, 955-960.	1.3	1
86	Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report. Journal of Medical Case Reports, 2018, 12, 50.	0.8	5
87	Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair. Cell Death and Disease, 2018, 9, 543.	6.3	42
88	Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study. Hepatology International, 2018, 12, 456-464.	4.2	13
89	A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study. Scientific Reports, 2018, 8, 8608.	3.3	4
90	Thyroid hormone negatively regulates tumorigenesis through suppression of BC200. Endocrine-Related Cancer, 2018, 25, 967-979.	3.1	18

#	Article	IF	Citations
91	Identification of Functional Thyroid Stimulating Hormone Receptor and TSHR Gene Mutations in Hepatocellular Carcinoma. Anticancer Research, 2018, 38, 2793-2802.	1.1	17
92	Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy. Journal of Medical Virology, 2017, 89, 153-160.	5.0	6
93	Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. BMC Infectious Diseases, 2017, 17, 9.	2.9	1
94	Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. Journal of Proteomics, 2017, 157, 40-51.	2.4	7
95	The long non-coding RNA LINC01013 enhances invasion of human anaplastic large-cell lymphoma. Scientific Reports, 2017, 7, 295.	3.3	31
96	A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients. Scientific Reports, 2017, 7, 523.	3.3	32
97	Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression. International Journal of Cancer, 2017, 140, 1581-1596.	5.1	34
98	Diabetes, hepatocellular carcinoma, and mortality in hepatitis Câ€infected patients: A populationâ€based cohort study. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1355-1362.	2.8	29
99	Thyroid hormone inhibits growth of hepatoma cells through induction of miR-214. Scientific Reports, 2017, 7, 14868.	3.3	21
100	High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma. Scientific Reports, 2017, 7, 10750.	3.3	31
101	GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma. Oncology Letters, 2017, 13, 4215-4223.	1.8	16
102	Recovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity. Amino Acids, 2017, 49, 291-302.	2.7	9
103	O-glycosylation in liver cancer: Clinical associations and potential mechanisms. Liver Research, 2017, 1, 193-196.	1.4	4
104	Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008–2012. Emerging Infectious Diseases, 2017, 23, 820-821.	4.3	4
105	The Evolving Interplay among Abundant Adipokines in Patients with Hepatitis C during Viral Clearance. Nutrients, 2017, 9, 570.	4.1	7
106	Roles of Long Noncoding RNAs in Recurrence and Metastasis of Radiotherapy-Resistant Cancer Stem Cells. International Journal of Molecular Sciences, 2017, 18, 1903.	4.1	66
107	GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 29151-29160.	1.8	20
108	Analyses of a whole-genome inter-clade recombination map of hepatitis delta virus suggest a host polymerase-driven and viral RNA structure-promoted template-switching mechanism for viral RNA recombination. Oncotarget, 2017, 8, 60841-60859.	1.8	11

#	Article	IF	CITATIONS
109	Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1 $\hat{l}\pm$ inactivation. Oncotarget, 2017, 8, 82280-82293.	1.8	33
110	Proteome-based identification of apolipoprotein A-IV as an early diagnostic biomarker in liver fibrosis. Oncotarget, 2017, 8, 88951-88964.	1.8	15
111	Intrahepatic HCV RNA Level and Genotype 1 Independently Associate with Hepatic Reticulon 3 Expression. Anticancer Research, 2017, 37, 2885-2891.	1.1	3
112	Clinical Predictors for Neutrophil–to–Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment. In Vivo, 2017, 31, 723-729.	1.3	9
113	Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008–2012. Emerging Infectious Diseases, 2017, 23, 820-821.	4.3	2
114	<i>GALNT14</i> genotype-guided, sorafenib in combination with transarterial chemoembolization in hepatocellular carcinoma: An interim report of a prospective randomized controlled trial Journal of Clinical Oncology, 2017, 35, e15657-e15657.	1.6	0
115	Systematic revelation of the protective effect and mechanism of <i>Cordycep sinensis</i> on diethylnitrosamine-induced rat hepatocellular carcinoma with proteomics. Oncotarget, 2016, 7, 60270-60289.	1.8	17
116	The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma. Medicine (United States), 2016, 95, e3284.	1.0	43
117	OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma. Molecular Carcinogenesis, 2016, 55, 366-375.	2.7	56
118	UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy. Scientific Reports, 2016, 6, 34088.	3.3	4
119	Thyroid hormone suppresses hepatocarcinogenesis via DAPK2 and SQSTM1-dependent selective autophagy. Autophagy, 2016, 12, 2271-2285.	9.1	45
120	Resistin reinforces interferon \hat{l} »-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Scientific Reports, 2016, 6, 30799.	3.3	24
121	Hepatitis B viremia in completely immunized individuals negative for anti-hepatitis B core antibody. Medicine (United States), 2016, 95, e5625.	1.0	11
122	GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy. Medicine (United States), 2016, 95, e3487.	1.0	19
123	Ubiquitination and filamentous structure of cytidine triphosphate synthase. Fly, 2016, 10, 108-114.	1.7	17
124	Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection. Clinical Cancer Research, 2016, 22, 1800-1812.	7.0	25
125	Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. Journal of Infectious Diseases, 2016, 213, 966-974.	4.0	60
126	<i>GALNT14</i> genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Pharmacogenomics, 2016, 17, 353-366.	1,3	20

#	Article	IF	Citations
127	HBV polymerase overexpression due to large core gene deletion enhances hepatoma cell growth by binding inhibition of microRNA-100. Oncotarget, 2016, 7, 9448-9461.	1.8	8
128	ChIP-on-chip analysis of thyroid hormone-regulated genes and their physiological significance. Oncotarget, 2016, 7, 22448-22459.	1.8	16
129	Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF- $\hat{11}$ activity and inhibiting epithelial-mesenchymal transition. Oncotarget, 2016, 7, 43588-43603.	1.8	59
130	Automated biphasic morphological assessment of hepatitis B-related liver fibrosis using second harmonic generation microscopy. Scientific Reports, 2015, 5, 12962.	3.3	33
131	Detection of serum anti-NV-F antibodies in the convalescent phase of severe hepatitis in patients positive for tissue NV-F antigen and novel virus-like particles. Journal of Medical Virology, 2015, 87, 1727-1736.	5.0	1
132	Impact of epidermal growth factor receptor protein and gene alteration on <scp>T</scp> aiwanese hepatocellular carcinomas. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1397-1404.	2.8	3
133	Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition. Oncotarget, 2015, 6, 23342-23357.	1.8	107
134	Detection of hepatitis D virus RNA carrying large fragment deletions in patients with severe hepatitis B/D receiving oral antiviral therapy. Journal of Medical Virology, 2015, 87, 634-641.	5.0	4
135	Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance. PLoS ONE, 2014, 9, e104783.	2.5	24
136	Granulocyte Colony-Stimulating Factor Reduces Fibrosis in a Mouse Model of Chronic Pancreatitis. PLoS ONE, 2014, 9, e116229.	2. 5	13
137	Complex IV subunit 1 defect predicts postoperative survival in hepatocellular carcinoma. Oncology Letters, 2014, 7, 1430-1438.	1.8	8
138	Decrease of Serum Angiotensin Converting Enzyme Levels Upon Telbivudine Treatment for Chronic Hepatitis B Virus Infection and Negative Correlations Between the Enzyme Levels and Estimated Glumerular Filtration Rates. Hepatitis Monthly, 2014, 14, e15074.	0.2	19
139	Genotyping the GALNT14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisons. Oncology Letters, 2014, 8, 2215-2220.	1.8	14
140	Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a caseâ€"control study. Scandinavian Journal of Gastroenterology, 2014, 49, 1456-1464.	1.5	15
141	Ribozyme-independent replication of a defective hepatitis D virus RNA derived from hepatitis B/D patients receiving antiviral therapy. Biochemical and Biophysical Research Communications, 2014, 450, 616-621.	2.1	0
142	A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. International Journal of Cancer, 2014, 134, 1214-1224.	5.1	27
143	Dysregulation of the TGFBI gene is involved in the oncogenic activity of the nonsense mutation of hepatitis B virus surface gene sW182*. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1080-1087.	3 . 8	8
144	Segregation of signaling proteins as prognostic predictors for local recurrence and distant metastasis in hepatocellular carcinoma. International Journal of Oncology, 2014, 44, 491-504.	3.3	4

#	Article	IF	CITATIONS
145	GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma. Molecular and Clinical Oncology, 2014, 2, 630-640.	1.0	16
146	Identification of Transforming Hepatitis B Virus S Gene Nonsense Mutations Derived from Freely Replicative Viruses in Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e89753.	2.5	21
147	OPN sesame. Hepatobiliary Surgery and Nutrition, 2014, 3, 112-4.	1.5	0
148	Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores. BMC Research Notes, 2013, 6, 212.	1.4	10
149	Liver Transplantation in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: The Influence of Viral Characteristics on Clinical Outcome. Annals of Surgical Oncology, 2013, 20, 3582-3590.	1.5	25
150	On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. BMC Research Notes, 2013, 6, 349.	1.4	3
151	Culturing of transgenic mice liver tissue slices in three-dimensional microfluidic structures of PEG-DA (poly(ethylene glycol) diacrylate). Sensors and Actuators B: Chemical, 2013, 176, 1081-1089.	7.8	9
152	Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e64891.	2.5	14
153	An Occult Hepatitis B-Derived Hepatoma Cell Line Carrying Persistent Nuclear Viral DNA and Permissive for Exogenous Hepatitis B Virus Infection. PLoS ONE, 2013, 8, e65456.	2.5	3
154	Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 39-48.	3.0	17
155	New Enzyme-Linked Immunosorbent Assay for Detection of Antibodies against Hepatitis Delta Virus Using a Hepatitis Delta Antigen Derived from a Taiwanese Clone and Comparison to the Abbott Radioimmunoassay. Vaccine Journal, 2012, 19, 817-819.	3.1	5
156	In-vitro transgenic mice liver tissue culture via hydrodynamic flow perfusion bioreactor. , 2012, , .		1
157	3D microstructure integrated bioreactor system for transgenic mice thick liver tissue culture. , 2012, , .		1
158	Eliminating hepatitis B virus through neonatal vaccination: Can we make it?. Journal of Hepatology, 2012, 57, 484-485.	3.7	7
159	Network analysis and proteomic identification of vimentin as a key regulator associated with invasion and metastasis in human hepatocellular carcinoma cells. Journal of Proteomics, 2012, 75, 4676-4692.	2.4	50
160	Increased Seroprevalence of HBV DNA With Mutations in the S Gene Among Individuals Greater Than 18 Years Old After Complete Vaccination. Gastroenterology, 2012, 143, 400-407.	1.3	59
161	Large Fragment Pre-S Deletion and High Viral Load Independently Predict Hepatitis B Relapse after Liver Transplantation. PLoS ONE, 2012, 7, e32189.	2.5	6
162	Identification of Postoperative Prognostic MicroRNA Predictors in Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e37188.	2.5	77

#	Article	IF	Citations
163	Furin Overexpression Suppresses Tumor Growth and Predicts a Better Postoperative Disease-Free Survival in Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e40738.	2.5	29
164	Peritumoral Small EphrinA5 Isoform Level Predicts the Postoperative Survival in Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e41749.	2.5	4
165	Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatology, 2012, 55, 910-920.	7. 3	66
166	SLC25A13 gene mutations in Taiwanese patients with non-viralhepatocellular carcinoma. Molecular Genetics and Metabolism, 2011, 103, 293-296.	1,1	20
167	<i>GALNT14</i> SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. Pharmacogenomics, 2011, 12, 1061-1073.	1.3	37
168	HURP Expression-Assisted Risk Scores Identify Prognosis Distinguishable Subgroups in Early Stage Liver Cancer. PLoS ONE, 2011, 6, e26323.	2.5	17
169	Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. BMC Cancer, 2011, 11, 117.	2.6	17
170	Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer, 2011, 11, 398.	2.6	48
171	Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. Hepatology, 2011, 54, 101-108.	7. 3	34
172	Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antiviral Therapy, 2010, 15, 471-475.	1.0	50
173	Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology, 2010, 52, 1922-1933.	7.3	76
174	Infection with hepatitis B virus carrying novel pre-S/S gene mutations in female siblings vaccinated at birth: two case reports. Journal of Medical Case Reports, 2010, 4, 190.	0.8	5
175	CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer, 2009, 9, 324.	2.6	38
176	293 cells overâ€expressing human ADI1 and CD81 are permissive for serumâ€derived hepatitis C virus infection. Journal of Medical Virology, 2009, 81, 1560-1568.	5.0	10
177	Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. Journal of Clinical Virology, 2009, 45, 114-118.	3.1	43
178	Expression of the <i>HCRP1</i> mRNA in HCC as an independent predictor of diseaseâ€free survival after surgical resection. Hepatology Research, 2009, 39, 164-176.	3.4	18
179	Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antiviral Therapy, 2009, 14, 249-61.	1.0	11
180	Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antiviral Therapy, 2009, 14, 249-261.	1.0	34

#	Article	IF	Citations
181	Impact of the Novel Hepatotropic Viruslike Agent NVâ€F during Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2008, 198, 1742-1748.	4.0	3
182	The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antiviral Therapy, 2008, 13, 875-9.	1.0	26
183	The Oncogenic Potential of Hepatitis B virus rtA181T/ Surface Truncation Mutant. Antiviral Therapy, 2008, 13, 875-879.	1.0	69
184	Identification of a Hepatitis B Virus S Gene Mutant in Lamivudine-Treated Patients Experiencing HBsAg Seroclearance. Gastroenterology, 2007, 132, 543-550.	1.3	64
185	Identification of a novel actin isoform in hepatocellular carcinoma. Hepatology Research, 2006, 36, 33-39.	3.4	22
186	Emergence and takeover of precore-stop mutant prior to exacerbation of e antigen-negative chronic hepatitis B after withdrawal of lamivudine therapy. Journal of Medical Virology, 2006, 78, 906-910.	5.0	21
187	Identification of a Novel Singleâ€Stranded DNA Fragment Associated with Human Hepatitis. Journal of Infectious Diseases, 2006, 193, 1089-1097.	4.0	15
188	A Novel Ex Vivo Assay of Interferonâ€Based Suppression, to Predict the Outcome of Antiviral Therapy for Hepatitis C. Journal of Infectious Diseases, 2006, 193, 1365-1370.	4.0	4
189	Anti-sense expression of a metallopeptidase gene enhances nuclear entry of HBV-DNA. Biochemical and Biophysical Research Communications, 2004, 323, 32-37.	2.1	2
190	No Benefit to Continue Lamivudine Therapy after Emergence of Ymdd Mutations. Antiviral Therapy, 2004, 9, 257-262.	1.0	71
191	Antisense overexpression of BMAL2 enhances cell proliferation. Oncogene, 2003, 22, 5306-5314.	5.9	27
192	Inhibition of authentic hepatitis C virus replication by sodium stibogluconate. Biochemical and Biophysical Research Communications, 2003, 310, 537-541.	2.1	16
193	Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. Biochemical and Biophysical Research Communications, 2003, 305, 311-314.	2.1	24
194	Epidemiological characteristics, risk factors, and clinical manifestations of acute non-A-E hepatitis. Journal of Medical Virology, 2001, 65, 296-300.	5.0	16
195	Identification of a Hepatic Factor Capable of Supporting Hepatitis C Virus Replication in a Nonpermissive Cell Line. Journal of Virology, 2001, 75, 11017-11024.	3.4	31
196	Hepatitis B virus X protein: Searching for a role in hepatocarcinogenesis. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 339-341.	2.8	29
197	Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene, 2000, 19, 5213-5220.	5.9	61
198	Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology, 2000, 31, 1318-1326.	7.3	204

#	Article	IF	CITATION
199	Prednisolone Priming Enhances Th1 Response and Efficacy of Subsequent Lamivudine Therapy in Patients With Chronic Hepatitis B. Hepatology, 2000, 32, 604-609.	7.3	90
200	Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clinical Endocrinology, 1999, 50, 503-509.	2.4	92
201	Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology, 1999, 30, 567-572.	7.3	535
202	Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer, 1999, 86, 1143-1150.	4.1	161
203	Etiology of sporadic acute viral hepatitis in Taiwan: The role of hepatitis C virus, hepatitis E virus and GB virus-C/hepatitis G virus in an endemic area of hepatitis A and B., 1999, 58, 154-159.		29
204	Progression of the proportion of hepatitis B virus precore stop mutant following acute superinfection of hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 131-136.	2.8	10
205	Efficacy of thymosin ?1 in patients with chronic hepatitis B: A randomized, controlled trial. Hepatology, 1998, 27, 1383-1387.	7.3	127
206	Detection of Helicobacter pylori by polymerase chain reaction assay using gastric biopsy specimens taken for CLOtest. Journal of Gastroenterology, 1996, 31, 329-332.	5.1	16
207	Serum levels of interferon- \hat{l}_{\pm} and- \hat{l}_{3} in acute and chronic hepatitis B virus infection. Digestive Diseases and Sciences, 1995, 40, 2107-2112.	2.3	22
208	Absence Of Precore Stop Mutant In Chronic Dual (B And C) And Triple (B, C, And D) Hepatitis Virus Infection. Journal of Infectious Diseases, 1994, 170, 1582-1585.	4.0	27